{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T12:30:12Z","timestamp":1752669012609,"version":"3.37.3"},"reference-count":55,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021772","name":"Deanship of Scientific Research, University of Jordan","doi-asserted-by":"publisher","award":["203\/2014"],"award-info":[{"award-number":["203\/2014"]}],"id":[{"id":"10.13039\/501100021772","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Aims<\/jats:title>\n<jats:p>This study aims to investigate the influence of <jats:italic>MEF2A<\/jats:italic> and <jats:italic>SLC22A3-LPAL2-LPA<\/jats:italic> polymorphisms on cardiovascular disease susceptibility and responsiveness to warfarin medication in Jordanian patients, during the initiation and maintenance phases of treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Backgrounds<\/jats:title>\n<jats:p>Several candidate genes have been reported to be involved in warfarin metabolism and studying such genes may help in finding an accurate way to determine the needed warfarin dose to lower the risk of adverse drug effects, resulting in more safe anticoagulant therapy.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Methods<\/jats:title>\n<jats:p>The study population included 212 cardiovascular patients and 213 healthy controls. Genotyping of <jats:italic>MEF2A<\/jats:italic> and <jats:italic>SLC22A3-LPAL2-LPA<\/jats:italic> polymorphisms was conducted to examine their effects on warfarin efficiency and cardiovascular disease susceptibility using PCR-based methods.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Results<\/jats:title>\n<jats:p>One SNP (SLC22A3-LPAL2-LPA rs10455872) has been associated with cardiovascular disease in the Jordanian population, whereas the other SNPs in the MEF2A gene and SLC22A3-LPAL2-LPA gene cluster did not have any significant differences between cardiovascular patients and healthy individuals. Moreover, SLC22A3-LPAL2-LPA rs10455872 was correlated with moderate warfarin sensitivity, the other SNPs examined in the current study have not shown any significant associations with warfarin sensitivity and responsiveness.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Our data refer to a lack of correlation between the MEF2A polymorphism and the efficacy of warfarin treatment in both phases of treatment, the initiation, and maintenance phases. However, only rs10455872 SNP was associated with sensitivity to warfarin during the initiation phase. Furthermore, rs3125050 has been found to be associated with the international normalized number treatment outcomes in the maintenance phase.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0294226","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T18:25:52Z","timestamp":1699640752000},"page":"e0294226","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of MEF2A and SLC22A3-LPAL2-LPA gene polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-0190","authenticated-orcid":true,"given":"Laith N.","family":"AL-Eitan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayah Y.","family":"Almasri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adan H.","family":"Alnaamneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Mihyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,11,10]]},"reference":[{"issue":"1","key":"pone.0294226.ref001","first-page":"1","article-title":"Polymorphisms in genes encoding metalloproteinase 9 and lymphotoxin-alpha can influence warfarin treatment","volume":"6","author":"J.B. Borges","year":"2015","journal-title":"Journal of Pharmacogenomics & Pharmacoproteomics"},{"issue":"12","key":"pone.0294226.ref002","doi-asserted-by":"crossref","first-page":"e0168732","DOI":"10.1371\/journal.pone.0168732","article-title":"The impact of genetic and non-genetic factors on warfarin dose prediction in MENA region: a systematic review","volume":"11","author":"L.A. Bader","year":"2016","journal-title":"PloS one"},{"issue":"6","key":"pone.0294226.ref003","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"133","author":"J. Ansell","year":"2008","journal-title":"Chest"},{"issue":"5","key":"pone.0294226.ref004","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S1734-1140(13)71496-8","article-title":"Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients.","volume":"65","author":"S. Natarajan","year":"2013","journal-title":"Pharmacological Reports"},{"issue":"1","key":"pone.0294226.ref005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2006.10.021","article-title":"Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1\u2014rationale and perspectives","volume":"120","author":"T. Yin","year":"2007","journal-title":"Thrombosis research"},{"issue":"11","key":"pone.0294226.ref006","doi-asserted-by":"crossref","first-page":"893","DOI":"10.7326\/0003-4819-139-11-200312020-00007","article-title":"Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism","volume":"139","author":"L.-A. Linkins","year":"2003","journal-title":"Annals of internal medicine"},{"issue":"1","key":"pone.0294226.ref007","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11239-007-0104-y","article-title":"Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues","volume":"25","author":"B.F. Gage","year":"2008","journal-title":"Journal of thrombosis and thrombolysis"},{"key":"pone.0294226.ref008","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cca.2013.07.010","article-title":"C3435T polymorphism of MDR1 gene with warfarin resistance","volume":"425","author":"Y. Kim","year":"2013","journal-title":"Clinica Chimica Acta"},{"issue":"1","key":"pone.0294226.ref009","doi-asserted-by":"crossref","first-page":"8S","DOI":"10.1378\/chest.119.1_suppl.8S","article-title":"Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range","volume":"119","author":"J. Hirsh","year":"2001","journal-title":"Chest"},{"issue":"1","key":"pone.0294226.ref010","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1365-2141.2004.05162.x","article-title":"The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants","volume":"127","author":"L.E. Visser","year":"2004","journal-title":"British journal of haematology"},{"issue":"3","key":"pone.0294226.ref011","doi-asserted-by":"crossref","first-page":"204S","DOI":"10.1378\/chest.126.3_suppl.204S","article-title":"The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"J. Ansell","year":"2004","journal-title":"Chest"},{"issue":"10","key":"pone.0294226.ref012","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/01.fpc.0000174789.77614.68","article-title":"Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population","volume":"15","author":"D.L. Veenstra","year":"2005","journal-title":"Pharmacogenetics and genomics"},{"issue":"12","key":"pone.0294226.ref013","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3390\/genes9120578","article-title":"Impact of CYP2C9 and VKORC1 Polymorphisms on Warfarin Sensitivity and Responsiveness in Jordanian Cardiovascular Patients during the Initiation Therapy.","volume":"9","author":"L. AL-Eitan","year":"2018","journal-title":"Genes"},{"key":"pone.0294226.ref014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/PGPM.S189458","article-title":"Effects of coagulation factor VII polymorphisms on warfarin sensitivity and responsiveness in Jordanian cardiovascular patients during the initiation and maintenance phases of warfarin therapy","author":"L.N. Al-Eitan","year":"2019","journal-title":"Pharmacogenomics and personalized medicine"},{"journal-title":"Warfarin Pharmacogenetics","year":"2007","author":"Springer","key":"pone.0294226.ref015"},{"issue":"10","key":"pone.0294226.ref016","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa0708078","article-title":"Genetic determinants of response to warfarin during initial anticoagulation","volume":"358","author":"U.I. Schwarz","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"17","key":"pone.0294226.ref017","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1182\/blood-2008-09-176859","article-title":"Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy","volume":"113","author":"C. Li","year":"2009","journal-title":"Blood"},{"issue":"3","key":"pone.0294226.ref018","doi-asserted-by":"crossref","first-page":"e1000433","DOI":"10.1371\/journal.pgen.1000433","article-title":"A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose","volume":"5","author":"F. Takeuchi","year":"2009","journal-title":"PLoS genetics"},{"issue":"3","key":"pone.0294226.ref019","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/ng.314","article-title":"Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease","volume":"41","author":"D.-A. Tr\u00e9gou\u00ebt","year":"2009","journal-title":"Nature genetics"},{"issue":"2","key":"pone.0294226.ref020","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1136\/jmg.2005.035071","article-title":"The Pro279Leu variant in the transcription factor MEF2A is associated with myocardial infarction","volume":"43","author":"P. Gonz\u00e1lez","year":"2006","journal-title":"Journal of medical genetics"},{"issue":"5650","key":"pone.0294226.ref021","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1126\/science.1088477","article-title":"Mutation of MEF2A in an inherited disorder with features of coronary artery disease","volume":"302","author":"L. Wang","year":"2003","journal-title":"Science"},{"issue":"10","key":"pone.0294226.ref022","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1161\/01.RES.0000072977.86706.23","article-title":"Roles of cardiac transcription factors in cardiac hypertrophy","volume":"92","author":"H. Akazawa","year":"2003","journal-title":"Circulation research"},{"issue":"1","key":"pone.0294226.ref023","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1476-511X-11-128","article-title":"Lack of association between four SNPs in the SLC22A3-LPAL2-LPA gene cluster and coronary artery disease in a Chinese Han population: a case control study.","volume":"11","author":"X. Lv","year":"2012","journal-title":"Lipids in health and disease"},{"key":"pone.0294226.ref024","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nature05911","article-title":"Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls","volume":"447","author":"N.J. Craddock","year":"2007","journal-title":"Nature"},{"issue":"11","key":"pone.0294226.ref025","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/FPC.0b013e32833fe789","article-title":"Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin","volume":"20","author":"L. Chen","year":"2010","journal-title":"Pharmacogenetics and genomics"},{"issue":"3","key":"pone.0294226.ref026","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1254\/jphs.09331SC","article-title":"Functional analysis of human organic cation transporter OCT3 (SLC22A3) polymorphisms","volume":"113","author":"T. Sakata","year":"2010","journal-title":"Journal of pharmacological sciences"},{"issue":"3","key":"pone.0294226.ref027","first-page":"296","article-title":"Genetic and clinical correlates of early-outgrowth colony-forming units","volume":"4","author":"S.Y. Shaw","year":"2011","journal-title":"Circulation: Cardiovascular Genetics"},{"issue":"9","key":"pone.0294226.ref028","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.1074\/jbc.M114.584953","article-title":"A solute carrier family 22 member 3 variant rs3088442 G\u2192 A associated with coronary heart disease inhibits lipopolysaccharide-induced inflammatory response","volume":"290","author":"L. Li","year":"2015","journal-title":"Journal of Biological Chemistry"},{"issue":"24","key":"pone.0294226.ref029","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1093\/hmg\/ddh329","article-title":"Transcription factor MEF2A mutations in patients with coronary artery disease","volume":"13","author":"M.K. Bhagavatula","year":"2004","journal-title":"Human molecular genetics"},{"issue":"2","key":"pone.0294226.ref030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.29252\/ijcp-25001","article-title":"9P21. 3 locus; An important region in coronary artery disease: a panel approach to investigation of the coronary artery disease etiology","volume":"4","author":"S. Omidi","year":"2019","journal-title":"Int J Cardiovasc Pract"},{"key":"pone.0294226.ref031","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2147\/IJGM.S298597","article-title":"Variants in CDHR3, CACNAC1, and LTA Genes Predisposing Sensitivity and Response to Warfarin in Patients with Cardiovascular Disease.","author":"M.A. Alghamdi","year":"2021","journal-title":"International Journal of General Medicine"},{"issue":"3","key":"pone.0294226.ref032","doi-asserted-by":"crossref","first-page":"826","DOI":"10.7150\/ijms.51546","article-title":"Influence of CYP4F2, ApoE, and CYP2A6 gene polymorphisms on the variability of Warfarin dosage requirements and susceptibility to cardiovascular disease in Jordan","volume":"18","author":"L.N. Al-Eitan","year":"2021","journal-title":"International journal of medical sciences"},{"issue":"3","key":"pone.0294226.ref033","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3390\/jpm10030117","article-title":"Influence of SH2B3, MTHFD1L, GGCX, and ITGB3 Gene Polymorphisms on theVariability on Warfarin Dosage Requirements and Susceptibility to CVD in the Jordanian Population","volume":"10","author":"L.N. Al-Eitan","year":"2020","journal-title":"Journal of Personalized Medicine"},{"issue":"4","key":"pone.0294226.ref034","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jsps.2019.01.011","article-title":"Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy","volume":"27","author":"L.N. Al-Eitan","year":"2019","journal-title":"Saudi Pharmaceutical Journal"},{"journal-title":"Anonymous, Standaard Afhandeling Cumarine Interacties","year":"2003","key":"pone.0294226.ref035"},{"key":"pone.0294226.ref036","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/PGPM.S189838","article-title":"Impact of a variable number tandem repeat in the CYP2C9 promoter on warfarin sensitivity and responsiveness in Jordanians with cardiovascular disease","volume":"12","author":"L.N. Al-Eitan","year":"2019","journal-title":"Pharmacogenomics and personalized medicine"},{"issue":"4","key":"pone.0294226.ref037","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein (a) concentration and the risk of coronary heart diseasestroke, and nonvascular mortality.","volume":"302","author":"E.R.F. Collaboration","year":"2009","journal-title":"JAMA: the journal of the American Medical Association"},{"issue":"9","key":"pone.0294226.ref038","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1161\/ATVBAHA.116.307311","article-title":"Functional variant in the SLC22A3-LPAL2-LPA gene cluster contributes to the severity of coronary artery disease","volume":"36","author":"L. Wang","year":"2016","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"26","key":"pone.0294226.ref039","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp (a) lipoprotein level and coronary disease","volume":"361","author":"R. Clarke","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"pone.0294226.ref040","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa0809329","article-title":"Estimation of the warfarin dose with clinical and pharmacogenetic data","volume":"360","author":"I.W.P. Consortium","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"13","key":"pone.0294226.ref041","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.287.13.1690","article-title":"Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy","volume":"287","author":"M.K. Higashi","year":"2002","journal-title":"Jama"},{"issue":"3","key":"pone.0294226.ref042","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.blre.2007.11.004","article-title":"Oral anticoagulants: Pharmacogenetics: Relationship between genetic and non-genetic factors.","volume":"22","author":"G. D\u2019Andrea","year":"2008","journal-title":"Blood reviews"},{"key":"pone.0294226.ref043","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/IJGM.S287238","article-title":"Impact of PCSK9, WDR12, CDKN2A, and CXCL12 polymorphisms in Jordanian cardiovascular patients on warfarin responsiveness and sensitivity","author":"R.K. Ibdah","year":"2021","journal-title":"International Journal of General Medicine"},{"key":"pone.0294226.ref044","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2147\/PGPM.S274246","article-title":"Influence of PSRC1, CELSR2, and SORT1 gene polymorphisms on the variability of warfarin dosage and susceptibility to cardiovascular disease","author":"L.N. Al-Eitan","year":"2020","journal-title":"Pharmacogenomics and Personalized Medicine"},{"issue":"2","key":"pone.0294226.ref045","doi-asserted-by":"crossref","first-page":"e31406","DOI":"10.1371\/journal.pone.0031406","article-title":"Variants in exon 11 of MEF2A gene and coronary artery disease: evidence from a case-control study, systematic review, and meta-analysis.","volume":"7","author":"Y. Liu","year":"2012","journal-title":"PloS one"},{"issue":"9","key":"pone.0294226.ref046","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10038-003-0054-y","article-title":"Identification of 46 novel SNPs in the 130-kb region containing a myocardial infarction susceptibility gene on chromosomal band 6p21","volume":"48","author":"A. Iida","year":"2003","journal-title":"Journal of human genetics"},{"issue":"6","key":"pone.0294226.ref047","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00439-011-0963-3","article-title":"Genetic contribution of the leukotriene pathway to coronary artery disease","volume":"129","author":"J. Hartiala","year":"2011","journal-title":"Human genetics"},{"issue":"2","key":"pone.0294226.ref048","first-page":"165","article-title":"Association and functional analyses of MEF2A as a susceptibility gene for premature myocardial infarction and coronary artery disease","volume":"2","author":"I. Guella","year":"2009","journal-title":"Circulation: Cardiovascular Genetics"},{"issue":"1","key":"pone.0294226.ref049","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.atherosclerosis.2009.09.005","article-title":"A study of the role of the myocyte-specific enhancer factor-2A gene in coronary artery disease","volume":"209","author":"S. Elhawari","year":"2010","journal-title":"Atherosclerosis"},{"issue":"4","key":"pone.0294226.ref050","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1172\/JCI24186","article-title":"Lack of MEF2A mutations in coronary artery disease","volume":"115","author":"L. Weng","year":"2005","journal-title":"The Journal of clinical investigation"},{"issue":"10","key":"pone.0294226.ref051","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1253\/circj.69.1192","article-title":"Assessment of MEF2A mutations in myocardial infarction in Japanese patients","volume":"69","author":"K. Kajimoto","year":"2005","journal-title":"Circulation Journal"},{"key":"pone.0294226.ref052","first-page":"1421","article-title":"LACK OF ASSOCIATION BETWEEN RS10755578 POLYMORPHISMS OF LIPOPROTEIN (A) GENE AND CORONARY ARTERY DISEASE IN IRANIAN POPULATION.","volume":"31","author":"M. Ahani","year":"2015","journal-title":"Acta Medica"},{"key":"pone.0294226.ref053","article-title":"The association between the LPA gene polymorphism and coronary artery disease in Chinese Han population","volume":"2014","author":"Z.-K. Song","year":"2014","journal-title":"BioMed research international"},{"issue":"3","key":"pone.0294226.ref054","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2174\/1875692113666150115221210","article-title":"Emergence of pharmacogenomics in academic medicine and public health in Jordan: History, present state and prospects.","volume":"12","author":"L. N Al-Eitan","year":"2014","journal-title":"Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics),"},{"issue":"1","key":"pone.0294226.ref055","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2174\/1875692115666161215103842","article-title":"Practical challenges and translational issues in pharmacogenomics and personalized medicine from 2010 onwards","volume":"14","author":"L. N AL-Eitan","year":"2016","journal-title":"Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics),"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0294226","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T18:26:13Z","timestamp":1699640773000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0294226"}},"subtitle":[],"editor":[{"given":"Asem Surindro","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":55,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0294226","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2023,11,10]]}}}